Compare Cassava Sciences Inc (FLNA) vs Redwire Corporation (RDW) Price & Performance

Filana Therapeutics (FLNA) trades at $0.82, down 6.77% today, amid bearish technical signals but with positive fundamental catalysts. The company shows improving quarterly EPS beats and a favorable EV/EBITDA of 1.03, though it remains unprofitable with negative cash flow. Recent FDA clearance for its epilepsy drug trial has generated optimism, reflected in strong analyst buy ratings (67% consensus).

The outlook balances clinical progress against financial strain. The FDA hold lift on simufilam provides a clear near-term catalyst for Phase 2a trials starting in 2027, supporting the bullish analyst view. However, high cash burn (-$33M net CF in 2025) and lack of revenue pose significant risks to sustainability, requiring careful monitoring of funding and trial milestones.

Redwire Corporation (RDW) trades at $10.24, down 3.58% today, with bearish technical signals despite strong analyst support. The company shows robust revenue growth with $335 million in 2025 and projected $426 million in 2026, though profitability remains challenged with negative net margins. Recent Space Force contract wins and partnerships position RDW in the expanding space infrastructure market, but cash flow concerns persist with negative operating cash flow.

RDW presents a high-risk growth opportunity with 80% analyst buy ratings and a $14.88 consensus target offering 45% upside. However, persistent losses, negative cash flow, and dependence on SpaceX's Starship success create significant volatility. The stock suits aggressive investors betting on space infrastructure growth despite current financial challenges.